Response to the comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al

Neuro Oncol. 2018 Jun 18;20(7):1004-1005. doi: 10.1093/neuonc/noy079.

Authors

Sujith K Joseph^{1

2

3}, Hebatalla Samaha^{1

2

3

4}, Kevin Bielamowicz^{1

2

3

5}, Nabil Ahmed^{1

2

3

4

5}

Affiliations

¹ Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, Texas, USA.
² Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
³ Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
⁴ The Children's Cancer Hospital of Egypt, Cairo, Egypt.
⁵ Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

No abstract available

Publication types

Comment

MeSH terms

Antigenic Variation
Brain Neoplasms*
Glioblastoma*
Humans
Interleukin-13 Receptor alpha2 Subunit*
T-Lymphocytes

Substances

Interleukin-13 Receptor alpha2 Subunit